Ensysce Biosciences, Inc. (ENSC) · Nov 4, 2026 · Exec change

Ensysce CEO change formalized as Kirkpatrick shifts to COO

CEO-to-COO transition — Kirkpatrick remains COO after the December 14 annual meeting

Ensysce’s executive-change filing formalizes James Morrison’s move to CEO while Lynn Kirkpatrick remains as COO after the December annual meeting.

Ensysce is a clinical-stage biotech now balancing its long-running PF614-MPAR overdose-protection program with CY200, the CRPS therapy added through its 2026 Cy Biopharma acquisition. The company has recently described CY200 as its lead pipeline asset while continuing late-stage work on PF614-MPAR.

The CEO handoff is mostly confirmation, not a new strategic shift. The company had already disclosed that President James Morrison would become CEO after stockholder approval; this filing adds that longtime CEO Lynn Kirkpatrick will move into the COO role rather than leave, preserving day-to-day scientific and operating continuity.

The transition avoids an immediate severance obligation. Kirkpatrick has agreed that accepting the COO position will not trigger severance under her employment agreement, limiting the financial complication of the succession.

The board change adds a small governance uncertainty but no stated operating disruption. Director Will Chang intends to resign after the annual meeting, but he has not submitted a written resignation or specified a date.

Bottom line: This formalizes a previously telegraphed leadership transition while retaining Kirkpatrick inside the operating team. It matters for governance and accountability, but it does not materially rewrite Ensysce’s clinical-development story.

What to watch next

Annual meeting, December 14, 2026

Original filing on SEC EDGAR

Ensysce CEO change formalized as Kirkpatrick shifts to COO | ENSC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.